Page 82 - Read Online
P. 82

Pazgan-Simon. Hepatoma Res 2020;6:17                             Hepatoma Research
               DOI: 10.20517/2394-5079.2019.52


               Review                                                                        Open Access


               Direct acting antivirals therapy and hepatocellular
               carcinoma risk in patients with hepatitis C virus


               Monika Pazgan-Simon

               Department of Infectious Diseases and Hepatology, Wroclaw Medical University, Wroclaw 51-149, Poland.
               Correspondence to: Monika Pazgan-Simon, MD, PhD, Department of Infectious Diseases and Hepatology, Wroclaw Medical
               University, Poland. E-mail: monikapazgansimon@gmail.com

               How to cite this article: Pazgan-Simon M. Direct acting antivirals therapy and hepatocellular carcinoma risk in patients with
               hepatitis C virus. Hepatoma Res 2020;6:17. http://dx.doi.org/10.20517/2394-5079.2019.52

               Received: 22 Dec 2019    First Decision: 18 Feb 2020    Revised: 16 Mar 2020    Accepted: 1 Apr 2020    Published: 10 Apr 2020
               Science Editor: Dalbir Singh Sandhu   Copy Editor: Jing-Wen Zhang    Production Editor: Tian Zhang


               Abstract
               The estimated number of people with active hepatitis C virus infection worldwide is about 70 million. The
               estimated number of people with active hepatitis C virus infection worldwide is about 70 million. Approximately
               30% of infected individuals develop cirrhosis, whilst some develop liver cancer, the fifth most common cancer
               worldwide. Currently available treatments, high-efficacy antiviral agents mostly short-term (8-12 weeks) and
               pangenotypic, have efficacy rates of over 96%. Some patients, especially those with cirrhosis, develop primary
               liver cancer even after effective hepatitis C virus treatment. In order to diagnose hepatocellular carcinoma early,
               patients at risk should be enrolled in a surveillance program.

               Keywords: Hepatitis C virus, direct acting antivirals treatment, oncogenesis



               INTRODUCTION
               The main causal agents in viral hepatitis are primary hepatotropic viruses: A (HAV), B (HBV), C (HCV), D
               (HDV), E (HEV). There are other secondary hepatotropic viruses that can also cause viral hepatitis.

               HCV is caused by the RNA virus of the Flaviviridae family, which has a single strand of 3011 bases and a
               lipid membrane envelope sized 60-70 nm. The virus structure encompasses a genome, core envelope proteins
                                                                                        [1,2]
               (E1, E2) and 7 non-structural proteins (NS1, NS2, NS3, NS4A, NS4B, NS5A and NS5B) .
               Hepatitis C is a blood-borne infection, transmitted as a result of skin impairment with non-sterile medical
               equipment, in particular intravenous drug injections and tattooing, during sex. This is especially the case
               for passive anal intercourse, vertically (from mother onto the child) during childbirth, and less often during



                           © The Author(s) 2020. Open Access This article is licensed under a Creative Commons Attribution 4.0
                           International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
                sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long
                as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license,
                and indicate if changes were made.


                                                                                                                                                    www.hrjournal.net
   77   78   79   80   81   82   83   84   85   86   87